Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Renalytix AI Plc (RTNXF)
OTHER OTC:RTNXF
Holding RTNXF?
Track your performance easily
RTNXF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.15 - $0.64
Previous Close$0.16
Volume10.00K
Average Volume (3M)10.00K
Market Cap
$32.54M
Enterprise Value$36.39M
Total Cash (Recent Filing)$4.68M
Total Debt (Recent Filing)$8.54M
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Nov 27, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding333,637,612
10 Day Avg. Volume0
30 Day Avg. Volume10,000
Standard Deviation0.55
R-Squared0.07
Alpha0.00481
Financial Highlights & Ratios
Price to Book (P/B)-1.78
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.04
Enterprise Value/Gross Profit233.30
Enterprise Value/Ebitda-1.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Renalytix AI News
PremiumCompany Announcements
Renalytix AI Targets Profitability with Kidney Test Sales
PremiumCompany Announcements
Renalytix Reports Reduced Losses and Strong Financial Outlook
PremiumCompany Announcements
Renalytix Sees Major Shift in Voting Rights
PremiumCompany Announcements
Renalytix PLC Sees Major Voting Rights Shift
PremiumCompany Announcements
Renalytix Adjusts Share Capital Amid Fundraising Shortfall
PremiumCompany Announcements
Renalytix Sees Major Stake Acquisition by Ruffer LLPPremiumCompany Announcements
Renalytix Appoints Julian Baines as Executive Chairman
PremiumCompany Announcements
Renalytix AI Sees Shift in Voting Rights ControlOwnership Overview
15.52% Insiders
0.05% Other Institutional Investors
84.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RTNXF FAQ
What was Renalytix AI Plc’s price range in the past 12 months?
Renalytix AI Plc lowest stock price was $0.15 and its highest was $0.64 in the past 12 months.
What is Renalytix AI Plc’s market cap?
Currently, no data Available
When is Renalytix AI Plc’s upcoming earnings report date?
Renalytix AI Plc’s upcoming earnings report date is Nov 27, 2024 which is in 4 days.
How were Renalytix AI Plc’s earnings last quarter?
Renalytix AI Plc released its earnings results on Oct 01, 2024. The company reported -$0.015 earnings per share for the quarter, beating the consensus estimate of -$0.02 by $0.005.
Is Renalytix AI Plc overvalued?
According to Wall Street analysts Renalytix AI Plc’s price is currently Overvalued.
Does Renalytix AI Plc pay dividends?
Renalytix AI Plc does not currently pay dividends.
What is Renalytix AI Plc’s EPS estimate?
Renalytix AI Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix AI Plc have?
Renalytix AI Plc has 331,206,020 shares outstanding.
What happened to Renalytix AI Plc’s price movement after its last earnings report?
Renalytix AI Plc reported an EPS of -$0.015 in its last earnings report, beating expectations of -$0.02. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Renalytix AI Plc?
Currently, no hedge funds are holding shares in RTNXF
---
Renalytix AI Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-73.97%
Trailing 12-Months
Company Description
Renalytix AI Plc
Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.
---
RTNXF Earnings Call
Q3 2024
0:00 / 0:00
---
Technical Analysis
---